BofA raised the firm’s price target on Humana (HUM) to $312 from $285 and keeps a Neutral rating on the shares. The firm is raising its price target to reflect higher peer multiples as well as the potential that Medicare Advantage is the next sector to rebound, but maintains a Neutral rating given the uncertain rate backdrop.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana Reaffirms 2025 Earnings Guidance in September Meeting
- Humana backs FY25 adjusted EPS $17.00, consensus $16.93
- Humana announces musculoskeletal care agreements with Vori Health, HOPCo
- Humana price target raised to $322 from $283 at RBC Capital
- Quipt Home Medical price target raised to $2.30 from $1.70 at Canaccord